
The current study intended to develop a new treatment of schizophrenia having a sustained release activity. Quetiapine fumarate (QF)-loaded polymer/lipid hybrid nanoparticulate systems of polycaprolactone (PCL) and Geleol™ were fabricated using polyvinyl alcohol (3% w/v). Results revealed the success of the optimum formulation in ameliorating the CPZ-induced behavioral disorders as well as in reducing the levels of cytokines, GABA and GFAP.
Like
Save
Share